Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase 2 Study of ET-743 in Persistent or Recurrent Endometrial Carcinoma
This study has been completed.
Study NCT00050440   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: December 9, 2002   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Endometrial Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms by Site
Urogenital Neoplasms
Uterine Diseases
Uterine Neoplasms
Interventions listed in this trial
ET-743
Additional drug interventions recognized in this trial
Ecteinascidin 743
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.
PharmaMar


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services